Introduction
Available for over a decade, the nucleoside analogue aciclovir has been the most extensively studied agent for the treatment of genital herpes. Recently, however, two new generation antiviral agents have become available, valaciclovir and famciclovir. It is therefore timely to review the scientific evidence in support of these antiherpes agents.
Understanding disease terminology is important in assessing treatment effectiveness. Primary genital herpes refers to the first episode occurring in a person who has not been infected previously with herpes simplex virus type 1 (HSV-1) or HSV-2. Such first episodes tend to be more severe than non-primary infections where an individual has been infected previously with HSV (either HSV-1 or HSV-2) in a non-genital site (usually orolabially). Recurrent infections are common sequelae of both first episode primary and non-primary infections, with individual frequency and severity depending primarily upon the virus type (HSV-2 tending to cause more severe and frequently recurring genital recurrences, compared with HSV-1). Recurrent episodes tend to be milder and shorter in duration than first episodes and are often associated with a recognizable prodrome of itching or genital awareness.
Therapeutic Management

First episodes
Having first been used for herpesvirus infections in immunocompromised patients in the early 1980s, aciclovir was first used in persons with severe genital herpes as an intravenous preparation. Mindel et af. (1982) , later followed by Corey et af. (1983) , reported that intravenous aciclovir, 5 mg kg-I three times daily for 5 days, in patients hospitalized throughout their infection, reduced the time to healing and virus shedding, compared with placebo.However, the number of treated patients was understandably small.
For the therapeutic management of uncomplicated first episode infections in immunocompetent patients, subsequent studies focused on topical treatment and/or oral aciclovir therapy. Corey et al. (1982) using aciclovir, 5% in polyethylene glycol ointment four times daily for 7 days, reported clinical benefit, especially in those with primary Only one study has evaluated the combination of topical 5% cream and oral aciclovir, 200 mg four times daily for 7 days in the treatment of first episode genital herpes (Kinghorn et al., 1986) . This study demonstrated that there was no clinical advantage gained by the addition of topical therapy for patients treated with oral aciclovir. Despite this, two UK studies found that 30% of genito urinary physicians (Russell et al., 1993) and one-third of general practitioners (Woolley & Chandiok, 1996) routinely prescribe this combination for first episode genital herpes.
Valaciclovir is the I-valyl ester of aciclovir, which, when given orally, produces three-fivefold greater serum levels of aciclovir than does oral aciclovir. Glasgow, Scotland, 14-17 May 1996) (Fig. 1 ). There were no significant differences in adverse events between the two groups, although headaches were more commonly reported in the valaciclovir-treated group than the aciclovir-treated group (14% versus 10%).
Oral famciclovir is the prodrug of the active agent penciclovir triphosphate. The latter has a long intracellular half-life in vitro (10 h for HSV-1-infected cells and 20 h for HSV-2-infected cells), compared with aciclovir (:S;1 h). In three dose-ranging studies of different durations of therapy, famciclovir, 250 mg three times daily for 5 or 10 days, was shown to be comparable to aciclovir, 200 mg five times daily (with regard to time to healing of lesion and adverse events) for the same treatment period (Loveless M, Harris W & Sacks S. Treatment of first episode genital herpes with famciclovir. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, 17-20 September 1995) (Fig. 2) . The adverse event profile for famciclovir was shown to be comparable to that of aciclovir.
Studies in a murine infection model have shown that early therapy with oral famciclovir can reduce reactivation of latent virus in this model system (Thackray & Field, 1996 ; also see Field &Thackray in this supplement). This suggests that famciclovir may reduce the likelihood of reactivation following early treatment during the primary infection. Supporting evidence comes from clinical observations reported by the author (Woolley PD (1983) in patients treated with topical aciclovir cream, five times daily, until lesions had healed. Although Bryson et al. (1983) was the first to report the clinical effectiveness of oral aciclovir (200 mg five times daily for 10 days) for treating first episodes (both primary and non-primary infections) of genital herpes, a much larger study by Mertz et al. (1984) gave more conclusive evidence of its efficacy (Table 2) . Oral aciclovir therapy became more popular than topical therapy, as the former was shown to reduce the mean time with constitutional symptoms by 50%, compared with placebo (3 days versus 6 days). Mindel et al. (1986) investigated the prolongation of treatment with oral aciclovir for up to 42 days. Although clinically effective for acute first episodes, prolonged oral aciclovir therapy was not shown to affect the rate of recurrent disease once treatment was discontinued (Mindel et al., 1986) . Oral aciclovir therapy is therefore licensed for 5 days' treatment in Europe (which can be extended to 10 days in severe infection) and 10 days in the USA for the treatment of first episode genital herpes. .: rienced recurrences. Only three of the patients receiving famciclovir returned with recurrences within 6 months, compared with 12 of the patients treated with aciclovir. A study is now in progress comparing the possible impact of famciclovir and valaciclovir on the course of disease in the treatment of primary genital herpes caused by HSV-2. The study has a 9-month follow-up period which should allow the investigators to determine whether famciclovir can prevent or reduce the establishment of latency. Positive results from this study would suggest that antiviral therapy can significantly affect the natural history of the condition. 
Recurrent episodes
As recurrent episodes are short-lived and self-limiting without treatment, most trials have required patients to self-initiate therapy, or to attend a clinic to have an antiviral prescribed within 24-48 h of symptoms or signs of a recurrence. Corey et al. (1982) was the first to report the clinical benefit of topical aciclovir 5% ointment in the treatment of recurrent genital herpes. However, clinical effectiveness seemed to be confined to men, with women receiving little clinical benefit (Table 3) . These findings were supported by a later study by Reichman et al. (1983) . As oral therapy had already become established by the early 1980s as the treatment of choice for first episodes of genital herpes, similar studies were conducted in the treatment of recurrent infection. The main difference was that therapy needed to be initiated earlier in the course of the clinical episode. One such large-scale study by compared oral aciclovir, 200 mg five times daily for 5 days, with placebo. TIlls was a cross-over study in which patients either attended a clinic within 48 h for clinician-initiated therapy, or self-initiated therapy within 24 h of an impending recurrence. Only modest clinical benefit was demonstrated and was greater when self-initiated (Fig. 3) . Despite little evidence of clinical benefit, topical aciclovir is prescribed by 34% ofgenitourinary physicians in the UK (Russell et al., 1993) Corey et al. (1982) . (n = 20)
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1.0 tioners in the UK (Woolley & Chandiok, 1996) . Similarly, although there is little evidence for a clinical benefit for oral aciclovir in this setting, it is prescribed by 30% of genitourinary physicians (Russell et al., 1993) and 43% of general practitioners (Woolley & Chandiok, 1996) . Valaciclovir has also been studied in the episodic treatment of individual recurrences of genital herpes. In a study of over 900 patients, Spruance et al. (1996) reported valaciclovir to be superior to placebo in reducing the length of clinical episode and time to lesion healing, when given twice-daily at a dose of either 1 g or 500 mg ( Table 4) . As with the first episode study there was no significant difference between the valaciclovir treatment groups.
Famciclovir has also been extensively studied in the treatment of recurrent genital herpes. Sacks et al. (1996) reported the results of a randomized, double-blind, frequent observation, dose-ranging study comparing twice-daily famciclovir, 125 mg, 250 mg, or 500 mg with placebo. Patients initiated therapy after self-culturing from lesions, reported to the clinic within 12 h and were assessed twicedaily for at least 5 days. Of those recruited, a total of 467 patients experienced a recurrence and self-initiated therapy. All doses of famciclovir reduced the onset and duration of virus shedding, lesion persistence and symptom duration, when compared with placebo (Fig. 4) . The incidence of side-effects reported in this trial were comparable between famciclovir and placebo, and there were no significant differences among the treatment groups.
Differences between the three antiviral agents have been noted for their impact on symptoms. Studies with aciclovir have not demonstrated effects on symptoms such as itching or pain (Nilsen et al, 1982; Reichman et al, 1984) . In contrast, valaciclovir has been shown to reduce the duration ofpain and episode duration, a measure of the time to cessation of all signs and symptoms (Spruance et al., 1996) , whereas famciclovir has been shown to significantly reduce the duration of pain, tenderness and itching, as well as all patient symptoms (Sacks et al., Reproduced with permission (Sacks et al., 1996 
Continuous suppressive therapy
Although there have been numerous studies reporting the effectiveness of continuous suppressive aciclovir therapy in reducing the frequency of recurrences of genital herpes, many have included only small numbers of patients. Of these, five have been reported in major peer-review journals and have more than 50 patients in the active treatment arm (Douglas eta!., 1984; Mindel etal., 1988; Mertzetal., 1988a; Mertz eta!., 1988b; Kinghorn et al., 1992) . A composite percentage of patients that were recurrence-free while taking different doses of aciclovir is shown in Table 5 . The clinical efficacy of aciclovir in suppressing recurrences appears to be related to the frequency of dosing rather than the total single dose; a feature to be expected in view of its short serum halflife (less frequent dosing being associated with increased incidence of breakthrough recurrences). A double-blind, placebo-controlled evaluation ofvalaciclovir, 500 mg once daily, for the suppression of genital herpes recurrences has been reported (Patel R, Crooks RJ, Bell SR & the European/Australian Valaciclovir HSV Mertz et 01., 19880, 19886. Conclusions greatest (78%) among those receiving famciclovir, 250 mg twice daily (hazard ratio, 3.6; 95% confidence interval, 1.9-6.9). Treatment with famciclovir, 125 mg twice daily and 250 mg once daily, also led to significant increases in the proportion who remained free of clinically confirmed recurrences: 62% and 60%, respectively (Fig. 5) . Treatment with famciclovir, 250 mg twice daily, gave the greatest increase in time to first virologically confirmed episode (hazard ratio, 7.1; 95% confidence interval, 2.8-18.5), with 90% remaining free from virologically confirmed recurrences. The adverse event profile was similar among those receiving famciclovir and those receiving placebo, including those treated at the highest doses.
The efficacy of famciclovir suppressive therapy given for 1 year has also been investigated (Diaz-Mitoma, Sibbald RG, Shafron SD & the Collaborative Famciclovir Genital Herpes Suppression Group. Famciclovir suppression of recurrent genital herpes. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA. 15-18 September 1996, Abstract Hll1). This study randomized patients to receive famciclovir, 125 mg three times daily, 250 mg twice daily, 250 three times daily or placebo. All three famciclovir doses significantly delayed the appearance of clinically confirmed recurrences compared with placebo (P= 0.0001). The proportion of patients who remained free from virologically confirmed episodes for at least 6 or 12 months was clinically and statistically superior for all famciclovir groups compared with placebo (P < 0.001). The efficacy was sustained over the 12-month period and all doses were very well tolerated.
Although results obtained from trials ofvalaciclovir and famciclovir cannot be compared direcdy with historical data from trials of suppressive aciclovir, the trials involving the new antiherpes agents continue to indicate that the more frequent the dosing regimen, the greater the reduction in breakthrough episodes. Aciclovir dose regimen daily, regimens; fewer patients, however, were recurrencefree on the once-daily regimens of valaciclovir.
The ability of famciclovir to suppress the recurrence of genital herpes has also been tested in a multicentre, placebocontrolled, dose-ranging trial in 375 women (Mertz et al., 1997) . Participants were randomized to receive either famciclovir, 125 mg once daily or twice daily, 250 mg once daily or twice daily, 500 mg once daily, or placebo for 4 months. The primary outcome measures included the time to first clinically and virologically confirmed recurrences. The proportion who remained free of clinically confirmed genital herpes episodes during the 120-day study was For first episodes of genital herpes the scientific evidence for the use of aciclovir points towards the use of oral therapy (200 mg five times daily), particularly for severe episodes. The role of topical aciclovir is less clear as it has no effect on constitutional symptoms and does not reduce the likelihood of further crops of lesions. There is no role for the combination of oral and topical aciclovir in the treatment of first episode infections. Both valaciclovir (1000 mg twice daily) and famciclovir (250 mg three times daily) have been shown to have comparable efficacy to aciclovir, while having the advantage of a reduced dosing frequency thus aiding the compliance.
Neither topical nor oral aciclovir have been shown to have a clinically significant benefit in the treatment of acute recurrent episodes. Both valaciclovir (500 mg twice daily) and farnciclovir (125 mg twice daily) have been shown to have clinically significant benefits, when compared with placebo, probably due to their favourable pharmacokinetic profiles. As with the treatment of first episodes, both of the newer antiviral agents have a reduced dosing frequency, when compared with acic1ovir.
Although continuous, suppressive antiviral therapy has been advocated for those with frequently recurring genital herpes, the most common indication reported by genitourinary physicians is to reduce the psychological morbidity associated with the unpredictability of recurrent episodes (Russell et al., 1993) . To this end, suppressive therapy should aim at reducing the number of clinically confirmed recurrences to a minimum. Continuous antiviral therapy has also been shown to reduce asymptomatic shedding. This is also likely to reduce the risk of transmission, but is yet to be demonstrated in a clinical study. Whatever the main aim of suppressive therapy, twice-daily dosing is likely to be more effective than once-daily therapy, especially where problems with compliance are encountered, since if a patient forgets to take one dose of a twice-daily regimen, they will be protected against viral reactivation for a longer period than if patients miss one dose of a once-daily regimen.
